Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) had its price target lifted by research analysts at Stifel Nicolaus from $80.00 to $82.00 in a note issued to investors on Thursday,Benzinga reports. Stifel Nicolaus’ price target would suggest a potential upside of 35.83% from the stock’s current price. Get Enliven Therapeutics alerts:Read Our Latest Research Report on ELVNEnliven Therapeutics Stock Up 1.1%NASDAQ ELVN traded up $0.67 during mid-day trading on Thursday, hitting $60.37. As a group, equities analysts anticipate that Enliven Therapeutics will post -1.57 earnings per share for the current fiscal year. Read MoreReceive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.